Kiromic Announces License Agreement With Longwood University for chPD1
Kiromic BioPharma, Inc. (Nasdaq: KRBP), an immuno-oncology
target discovery and gene-editing company, with a proprietary
artificial intelligence neural network platform (Diamond AI) to
develop novel oncology therapeutics, has announced the completion
of the chPD1 licensing agreement with Longwood University.
- PD-1 has always been a challenge for CAR-T development.
- PD-1 is the brakes of the immune system, inhibiting immune
cells from killing tumor cells. Traditional PD-1 inhibitors block
the PD-1 receptor, “removing the brakes” of T-cell activity.
- Kiromic’s chPD1 not only “removes the brakes” but also engages
the PD-1 receptor to “accelerate” T-cell activity.
- Upon interaction with the PD-1 ligand, the chPD1 receptor
activates CD3 zeta (the main activating intracellular domain for T
cells), and Dap10 (costimulatory domain). The activation of these
two intracellular domains induces T cell activation, cytokine
secretion, and tumor cell lysis.
"Longwood University is proud to have completed this chPD1
licensing agreement with Kiromic. We believe that Kiromic has a
strong Allogenic Off-The-Shelf CAR-T program which will be even
stronger with chPD1. The role that chPD1 plays in the modulation of
the tumor micro-environment (TME) can never be underestimated when
treating solid tumors," says Dr. Amorette Barber, PhD, Associate
Professor of Biology and Director of the Office of Student Research
at Longwood University.
"The completion of the licensing agreement for chPD1 marks a
major milestone for Kiromic CAR-T development. With chPD1, we
believe our chimeric PD1 CAR-T will be able to overcome the
challenging tumor micro-environment (TME) which has plagued other
CAR-T programs," says Dr. Maurizio Chiriva-Internati, PhD, CEO of
"We believe that the licensing agreement of chPD1 from Longwood
will make Kiromic the only CAR-T development program with a
built-in capability to meet other CAR-T programs head-on who do not
have a bundled chPD1 CAR-T. We believe that the licensing agreement
will place Kiromic in a solid position to begin first in-human in
solid tumors," says Mr. Gianluca Rotino, Chief of Strategy and
Innovation of Kiromic BioPharma.
About Longwood University
Longwood has a robust research department with 7 post doctorates
conducting research in molecular biology, microbiology, genomics,
cancer biology, and immunology and publishing over 75 publications
in different scientific journals in the past 5 years.
LINK to Longwood University: www.longwood.edu
Kiromic BioPharma, Inc. is an immuno-oncology biopharmaceutical
company focused on discovering, developing, and commercializing
novel immuno-oncology applications through its robust product
pipeline. The pipeline development is leveraged through the
Company’s proprietary target discovery engine called "DIAMOND."
Kiromic's DIAMOND is essentially big data science meeting target
identification, dramatically compressing the man-years and the
millions of drug development dollars needed to develop a live drug.
The Company’s headquarters are located in Houston, TX adjacent to
the world’s largest medical center and the MDACC.
For more information, please visit Kiromic’s website at:
This press release contains forward-looking statements that
involve substantial risks and uncertainties. We make such
forward-looking statements pursuant to the safe harbor provisions
of the U.S. Private Securities Litigation Reform Act, Section 21E
of the Securities Exchange Act of 1934, as amended, and other
federal securities laws. All statements other than statements of
historical facts are forward-looking statements. These statements
relate to future events or to our future financial performance and
involve known and unknown risks, uncertainties and other factors
that may cause our actual results, levels of activity, performance
or achievements to be materially different from any future results,
levels of activity, performance or achievements expressed or
implied by these forward-looking statements. Forward-looking
statements include, but are not limited to, statements about our
intentions, projections, assessments, or expectations regarding
items such as the following:
- our goals and strategies
- research, development, and regulatory activities
- FDA authorization timeline for clinical trial initiation
- clinical trial enrollment or participation by clinical
- facility manufacturing capabilities for clinical trial
- expectations related to gamma delta CAR therapy
- performance and success of clinical trials
- our future business development, financial condition, and
results of operations
- expected changes in our revenue, costs, or expenditures
- growth of and competition trends in our industry
- our expectations regarding demand for, and market acceptance
of, our products
- our expectations regarding our relationships with investors,
institutional funding partners and other parties we collaborate
- fluctuations in general economic and business conditions in the
markets in which we operate; including those fluctuations caused by
- relevant government policies and regulations relating to our
In some cases, you can identify forward-looking statements by
terms such as "may," "could," "will," "should," "would," "expect,"
"plan," "intend," "anticipate," "believe," "estimate," "predict,"
"potential," "project" or "continue" or the negative of these terms
or other comparable terminology. These statements are only
predictions. You should not place undue reliance on forward-looking
statements because they involve known and unknown risks,
uncertainties, and other factors, which are, in some cases, beyond
our control and which could materially affect results. Factors that
may cause actual results to differ materially from current
expectations include, among other things, those listed under the
heading "Risk Factors" included in our Registration Statement on
Form S-1 (file no. 333-238153), originally filed with the
Securities and Exchange Commission (SEC) on May 11, 2020, as
amended, and elsewhere in this press release. If one or more of
these risks or uncertainties occur, or if our underlying
assumptions prove to be incorrect, actual events or results may
vary significantly from those implied or projected by the
forward-looking statements. No forward-looking statement is a
guarantee of future performance.
The forward-looking statements made in this press release relate
only to events or information as of the date on which the
statements are made in this press release. Except as expressly
required by the federal securities laws, there is no undertaking to
publicly update or revise any forward-looking statements, whether
as a result of new information, future events, changed
circumstances or any other reason. You are advised, however, to
review any further disclosures we make on related subjects in our
Forms 10-Q, 8-K and other reports filed with the SEC.
version on businesswire.com: https://www.businesswire.com/news/home/20210126006078/en/
Tony Tontat Chief Financial Officer (844) 539 -